polycythemia vera (Cancer)
Information
- Disease name
- polycythemia vera
- Disease ID
- DOID:8997
- Description
- "A myeloproliferative neoplasm characterized by erythroid hyperplasia, myeloid leukocytosis, thrombocytosis, and splenomegaly." [url:https\://en.wikipedia.org/wiki/Polycythemia_vera, url:https\://rarediseases.info.nih.gov/diseases/7422/polycythemia-vera, url:https\://www.mayoclinic.org/diseases-conditions/polycythemia-vera/symptoms-causes/syc-20355850]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03862157 | Active, not recruiting | Phase 1/Phase 2 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | February 27, 2019 | January 31, 2025 |
| NCT04262141 | Active, not recruiting | Phase 2 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | October 2, 2020 | October 31, 2025 |
| NCT02493530 | Active, not recruiting | Phase 1 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | July 2015 | December 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT00588991 | Active, not recruiting | Phase 1 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | November 28, 2007 | March 7, 2025 |
| NCT05485948 | Active, not recruiting | Phase 2 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | October 8, 2021 | May 2025 |
| NCT04057040 | Active, not recruiting | Phase 2 | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | October 1, 2019 | January 1, 2026 |
| NCT05558696 | Active, not recruiting | Phase 2 | A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004) | September 7, 2023 | March 24, 2025 |
| NCT05269771 | Available | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | |||
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00381550 | Completed | Phase 2 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | August 2006 | March 2011 |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT00430066 | Completed | Phase 2 | Effects of Imatinib Mesylate in Polycythemia Vera | February 2007 | September 2012 |
| NCT00433862 | Completed | Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders | February 6, 2007 | May 19, 2010 | |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00509899 | Completed | Phase 1/Phase 2 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | June 2007 | February 2017 |
| NCT00586651 | Completed | Phase 2 | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis | December 2007 | September 2010 |
| NCT00665067 | Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders | April 2007 | July 20, 2018 | |
| NCT00666289 | Completed | Familial Myeloproliferative Disorders | March 2008 | June 20, 2015 | |
| NCT00666549 | Completed | Research Tissue Bank | September 2007 | March 27, 2017 | |
| NCT00715247 | Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes | July 2006 | December 2018 | |
| NCT00745550 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | August 2008 | January 2012 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00928707 | Completed | Phase 2 | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera | June 2009 | October 2011 |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01120821 | Completed | Phase 2 | Treatment of Polycythemia Vera With Gleevec | August 2002 | June 2007 |
| NCT01134120 | Completed | Phase 1 | A Study in Myeloproliferative Disorders | April 2010 | February 22, 2018 |
| NCT01193699 | Completed | Phase 1/Phase 2 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera | August 2010 | January 25, 2018 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01243073 | Completed | Phase 2 | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | December 2010 | April 2015 |
| NCT01243944 | Completed | Phase 3 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | October 27, 2010 | February 9, 2018 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01387763 | Completed | Phase 3 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms | January 2012 | June 2020 |
| NCT01499147 | Completed | N/A | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | February 2000 | May 2013 |
| NCT01520220 | Completed | Phase 1 | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | June 11, 2012 | February 24, 2017 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01632904 | Completed | Phase 3 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | June 2012 | May 2016 |
| NCT00946270 | Completed | Phase 2 | Pomalidomide for Myelofibrosis Patients | July 22, 2009 | May 22, 2018 |
| NCT00038675 | Completed | N/A | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | June 2001 | November 2013 |
| NCT00039416 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | April 2002 | |
| NCT00047190 | Completed | Phase 2 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | August 2002 | |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00227591 | Completed | Phase 2 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | December 2005 | December 2010 |
| NCT00241241 | Completed | Phase 2 | Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera | September 2004 | January 2008 |
| NCT00255346 | Completed | Phase 2 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | November 15, 2005 | March 3, 2017 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01787552 | Completed | Phase 1/Phase 2 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | May 8, 2013 | April 10, 2018 |
| NCT01831635 | Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study | April 2013 | June 2015 | |
| NCT01901432 | Completed | Phase 1/Phase 2 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | October 2013 | September 25, 2017 |
| NCT01949805 | Completed | Phase 3 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera | September 2013 | July 2016 |
| NCT01970930 | Completed | Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients | August 2012 | June 2, 2016 | |
| NCT01981850 | Completed | Phase 2 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | October 1, 2013 | July 10, 2020 |
| NCT02038036 | Completed | Phase 3 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | March 25, 2014 | April 7, 2020 |
| NCT02124746 | Completed | Phase 2 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | April 30, 2014 | December 6, 2018 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT02218047 | Completed | Phase 3 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. | November 2014 | April 29, 2021 |
| NCT02292446 | Completed | Phase 3 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | November 21, 2014 | December 29, 2017 |
| NCT02311569 | Completed | Phase 2 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | April 2015 | December 2016 |
| NCT02407080 | Completed | Phase 1 | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | April 2015 | December 19, 2018 |
| NCT02523638 | Completed | Phase 3 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients | July 2015 | December 2015 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT02823184 | Completed | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms | April 27, 2017 | April 27, 2019 | |
| NCT02893410 | Completed | Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients | December 2014 | December 2015 | |
| NCT02912884 | Completed | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure | September 2016 | October 31, 2020 | |
| NCT03003325 | Completed | Phase 2 | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV | February 2, 2017 | March 31, 2023 |
| NCT03065400 | Completed | Phase 2 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | June 14, 2017 | May 28, 2020 |
| NCT03745378 | Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) | May 15, 2018 | September 30, 2018 | |
| NCT03907436 | Completed | N/A | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | October 1, 2018 | October 1, 2019 |
| NCT04051307 | Completed | Phase 1/Phase 2 | Dual Vaccine Trial in Myeloproliferative Neoplasms | July 10, 2019 | July 10, 2022 |
| NCT04629508 | Completed | Phase 2 | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | July 12, 2021 | August 24, 2023 |
| NCT04767802 | Completed | Phase 2 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit | February 2, 2021 | March 15, 2023 |
| NCT05853445 | Completed | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera | August 17, 2015 | May 3, 2023 | |
| NCT06371573 | Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | April 20, 2017 | March 20, 2024 | |
| NCT06033586 | Enrolling by invitation | Phase 3 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | January 22, 2024 | April 1, 2027 |
| NCT05566535 | Not yet recruiting | Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice | October 1, 2022 | August 1, 2024 | |
| NCT06251102 | Not yet recruiting | Real-world Ruxolitinib Experience in PV | July 2024 | July 2025 | |
| NCT06290765 | Not yet recruiting | Phase 4 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera | July 1, 2024 | February 28, 2027 |
| NCT05548062 | Recruiting | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | March 2, 2023 | September 30, 2026 | |
| NCT06378437 | Recruiting | Phase 1 | A Study of GLB-001 in Patients With Myeloid Malignancies | May 24, 2024 | December 31, 2027 |
| NCT02386800 | Recruiting | Phase 4 | CINC424A2X01B Rollover Protocol | March 5, 2015 | September 16, 2027 |
| NCT05853458 | Recruiting | Phase 4 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | July 28, 2023 | December 31, 2026 |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT06093672 | Recruiting | Phase 3 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | March 26, 2024 | July 2026 |
| NCT05993065 | Recruiting | Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis. | December 15, 2022 | October 2023 | |
| NCT04116502 | Recruiting | Phase 3 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | October 25, 2019 | February 1, 2028 |
| NCT02760238 | Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry | April 2016 | October 2025 | |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT06351631 | Recruiting | Phase 3 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | May 23, 2024 | December 4, 2034 |
| NCT04644211 | Recruiting | Phase 2 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | March 21, 2022 | December 2024 |
| NCT06361641 | Recruiting | N/A | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | May 29, 2024 | October 19, 2027 |
| NCT05882773 | Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry | May 2023 | December 2026 | |
| NCT06134102 | Recruiting | Clinical and Laboratory Characteristics of Polycythemia Vera | January 1, 2019 | December 31, 2023 | |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05074550 | Recruiting | Phase 1 | Safety Evaluation Study for Patients With Polycythemia Vera | August 24, 2022 | March 31, 2024 |
| NCT05870475 | Recruiting | Phase 2 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV | May 30, 2023 | May 31, 2028 |
| NCT05123365 | Recruiting | Phase 1/Phase 2 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | January 3, 2022 | November 15, 2026 |
| NCT05198960 | Recruiting | Phase 3 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | July 13, 2022 | July 13, 2027 |
| NCT05210790 | Recruiting | Phase 3 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | April 1, 2022 | June 2025 |
| NCT05481151 | Recruiting | Phase 3 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | October 26, 2022 | December 28, 2025 |
| NCT02897297 | Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest | September 2015 | September 2025 | |
| NCT06063486 | Recruiting | Phase 2 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | March 1, 2024 | March 1, 2027 |
| NCT06218628 | Recruiting | Phase 1 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | April 5, 2024 | August 27, 2030 |
| NCT05499013 | Recruiting | Phase 1/Phase 2 | Study to Assess SLN124 in Patients With Polycythemia Vera | January 26, 2023 | June 2025 |
| NCT01998828 | Terminated | Phase 2 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | February 19, 2014 | May 7, 2015 |
| NCT03121599 | Terminated | N/A | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | June 11, 2017 | October 16, 2018 |
| NCT03287245 | Terminated | Phase 2 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | February 21, 2018 | March 3, 2020 |
| NCT01038856 | Terminated | Phase 2 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera | December 2009 | February 2014 |
| NCT01014546 | Terminated | Phase 1 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | April 2010 | February 2015 |
| NCT03972943 | Terminated | Early Phase 1 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | May 15, 2019 | July 28, 2023 |
| NCT01645124 | Terminated | Phase 3 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) | May 2008 | July 2012 |
| NCT00595829 | Terminated | Phase 1 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | December 2007 | February 2009 |
| NCT00538980 | Terminated | Phase 2 | Dasatinib in Polycythemia Vera | April 30, 2007 | August 27, 2010 |
| NCT00522574 | Terminated | Phase 1 | A Safety Study of XL019 in Adults With Myelofibrosis | August 2007 | |
| NCT01284712 | Unknown status | Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) | July 2009 | ||
| NCT01816022 | Unknown status | Myeloproliferative Neoplasms and Bone Structure | March 2012 | March 2015 | |
| NCT00668421 | Unknown status | Phase 1/Phase 2 | CEP-701 (Lestaurtinib) in Myelofibrosis | April 2008 | January 2015 |
| NCT02809274 | Unknown status | Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features | July 2016 | August 2018 | |
| NCT00866762 | Unknown status | Phase 2 | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | February 2009 | December 2012 |
| NCT03669965 | Unknown status | Phase 2 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | January 15, 2019 | October 2022 |
| NCT04896112 | Withdrawn | Phase 1 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | April 8, 2021 | October 20, 2022 |
| NCT02663648 | Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | June 2016 | June 2020 | |
| NCT00940784 | Withdrawn | Phase 2 | Clopidogrel and Aspirin for the Treatment of Polycythemia Vera | June 2009 | January 2011 |
| NCT02805868 | Withdrawn | Early Phase 1 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | June 2016 |
- Disase is a (Disease Ontology)
- DOID:2226
- Cross Reference ID (Disease Ontology)
- GARD:7422
- Cross Reference ID (Disease Ontology)
- ICD10CM:D45
- Cross Reference ID (Disease Ontology)
- ICD9CM:207.1
- Cross Reference ID (Disease Ontology)
- ICD9CM:238.4
- Cross Reference ID (Disease Ontology)
- ICDO:9950/3
- Cross Reference ID (Disease Ontology)
- MESH:D011087
- Cross Reference ID (Disease Ontology)
- MIM:263300
- Cross Reference ID (Disease Ontology)
- NCI:C3336
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154644004
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:188753004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0032463
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0152272
- Exact Synonym (Disease Ontology)
- chronic erythremia
- Exact Synonym (Disease Ontology)
- Osler-Vaquez syndrome
- Exact Synonym (Disease Ontology)
- Polycythaemia rubra vera
- Exact Synonym (Disease Ontology)
- Proliferative polycythaemia
- OrphaNumber from OrphaNet (Orphanet)
- 729
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011087